A Phase 3 interventional study of RGB-14-P and Prolia® in Postmenopausal Osteoporosis, sponsored by Gedeon Richter Plc.. Completed at 59 sites in 8 countries. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by Gedeon Richter Plc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Osteoporosis, Postmenopausal with a site in Poland — none open to participants now, 2 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · Poland.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, this one is the 23rd largest by enrollment, is one of 3 that started in 2021, is one of 27 in phase 3, and was the 30th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →None of the 36 studies in Osteoporosis, Postmenopausal with a site in Poland is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →
Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 60 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 473 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 543 across the 36 interventional studies. Of the 34 that completed or were terminated, 29 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
Gedeon Richter Plc. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Gedeon Richter Plc. has 1 study filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies in Osteoporosis, Postmenopausal with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06577935Angitia BiopharmaceuticalsA Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Osteoporosis, Postmenopausal with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be conducted to assess the efficacy, pharmacodynamic (PD), safety, tolerability, and immunogenicity of RGB -14- P compared to US-licensed Prolia® in participants with postmenopausal osteoporosis, in a comparative manner.
This is a randomized, double-blind, multicentre, multiple fixed-dose, 2-arm parallel-group study that includes 2 periods as:
All participants will receive the study drugs on 2 occasions (Weeks 0 and 26), on Day 1 of Treatment Periods 1 and 2. Participants continuing to the Transition Period will receive the study drugs on a third-occasion (Week 52), Day 1 of Treatment Period 3. One Treatment Period will take 6 months (26 weeks, 183 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet the following criteria to be enrolled in the Transition Period:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomized participants will receive subcutaneous (SC) injection of RGB-14-P, on Day 1 of Treatment periods 1 and 2.
Drug: RGB-14-P
Randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment periods 1 and 2.
Drug: Prolia®
Re-randomized participants will receive SC injection of RGB-14-P, on Day 1 of Treatment period 3.
Drug: RGB-14-P
Re-randomized participants will receive SC injection of Prolia®, on Day 1 of Treatment period 3.
Drug: Prolia®
Randomized participants will continue to receive SC injection of RGB-14-P from the main period till Day 1 of Treatment period 3.
Drug: RGB-14-P
Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD)
Percentage change from baseline in lumbar bone BMD was assessed. BMD at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). This outcome measure was assessed for main period.
Time frame: Week 52
Area Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX)
The AUEC of %CfB in sCTX of RGB-14-P was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants was demonstrated with postmenopausal osteoporosis. This outcome measure was assessed for main period only.
Time frame: Week 26
%CfB in Total Hip BMD
%CfB in total hip BMD was assessed.
Time frame: Weeks 26, 52 and 78
%CfB in Lumbar Spine BMD
%CfB in lumbar spine BMD was assessed.
Time frame: Weeks 26 and 78
%CfB in Femoral Neck BMD
%CfB in femoral neck BMD was assessed by DXA.
Time frame: Weeks 26, 52 and 78
Number of Participants With Vertebral Fragility Fracture
Number of participants with vertebral fragility fracture was assessed. Information on vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.
Time frame: Weeks 52 and 78
Number of Participants With Non-vertebral Fragility Fracture
Number of participants with non-vertebral fragility fracture was assessed. Information on non-vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.
Time frame: Weeks 52 and 78
%CfB in Serum Procollagen Type 1 N Terminal Propeptide (P1NP)
%CfB in serum P1NP was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants with postmenopausal osteoporosis.
Time frame: Weeks 4, 26, 52 and 78
%CfB in Serum Type I Collagen C-telopeptide (sCTX)
%CfB in sCTX was assessed as part of pharmacodynamics parameter with US-licensed Prolia® was assessed in female participants with postmenopausal osteoporosis.
Time frame: Weeks 4, 26, 52 and 78
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
The safety and tolerability of RGB-14-P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.
Time frame: Main Period: From screening (Weeks -5 to 0) to Week 52; Transition Period: From Week 52 to Week 78
Number of Participants With Anti-drug Antibodies (ADAs)
Number of participants with positive ADAs was assessed.
Time frame: Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78
Number of Participants With Neutralizing Antibodies
Number of participants with positive neutralizing antibodies was assessed.
Time frame: Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78
Titre of ADAs
The immunogenicity of RGB -14- P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.
Time frame: Weeks 0, 2, 4, 26, 28, 30, 52, 54, 56 and 78
The study was conducted between 21-September-2021 (first subject first visit) to 15-November-2023 (last subject last visit).
| Milestone | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Started | 242 | 231 | 0 | 0 | 0 |
| Completed | 225 | 211 | 0 | 0 | 0 |
| Not completed | 17 | 20 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 13 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Subject's personal reason | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Exclusion criteria met | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Study objective confounded by monoclonal gammopathy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 2 | 0 | 0 | 0 |
| Milestone | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Started | 0 | 0 | 63 | 62 | 63 |
| Completed | 0 | 0 | 63 | 62 | 62 |
| Not completed | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
Percentage change from baseline in lumbar bone BMD was assessed. BMD at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). This outcome measure was assessed for main period.
| Percentage change from baseline | Main Period: RGB-14-P | Main Period: Prolia® |
|---|---|---|
| Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD) | 5.68 ± 3.535 | 5.19 ± 4.118 |
The AUEC of %CfB in sCTX of RGB-14-P was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants was demonstrated with postmenopausal osteoporosis. This outcome measure was assessed for main period only.
| mg/dL*day | Main Period: RGB-14-P | Main Period: Prolia® |
|---|---|---|
| Area Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX) | 14609.67 ± 3142.086 | 14134.86 ± 7331.714 |
%CfB in total hip BMD was assessed.
| Percentage change from baseline | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 26 | 2.42 ± 2.659 | 2.69 ± 2.519 | 2.46 ± 2.712 | 2.81 ± 2.607 | 3.35 ± 2.559 |
| Week 52 | 3.42 ± 2.916 | 3.49 ± 2.872 | 3.03 ± 3.103 | 3.36 ± 2.696 | 4.21 ± 3.452 |
| Week 78 | — | — | 4.24 ± 3.381 | 4.12 ± 3.128 | 4.95 ± 3.849 |
%CfB in lumbar spine BMD was assessed.
| Percentage change from baseline | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 26 | 3.56 ± 3.747 | 3.45 ± 4.227 | 3.98 ± 3.185 | 3.39 ± 3.848 | 3.68 ± 4.979 |
| Week 78 | — | — | 7.03 ± 3.828 | 7.06 ± 4.327 | 7.09 ± 4.240 |
%CfB in femoral neck BMD was assessed by DXA.
| Percentage change from baseline | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 26 | 1.88 ± 3.040 | 1.94 ± 3.610 | 1.60 ± 2.833 | 2.21 ± 3.296 | 2.35 ± 4.057 |
| Week 52 | 2.42 ± 3.687 | 2.64 ± 3.751 | 1.95 ± 3.621 | 2.60 ± 3.127 | 3.24 ± 4.549 |
| Week 78 | — | — | 3.08 ± 4.259 | 3.06 ± 3.337 | 4.04 ± 4.764 |
Number of participants with vertebral fragility fracture was assessed. Information on vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.
| Participants | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 52 | 4 | 8 | — | — | — |
| Week 78 | — | — | 3 | 4 | 2 |
Number of participants with non-vertebral fragility fracture was assessed. Information on non-vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.
| Participants | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 52 | 4 | 10 | — | — | — |
| Week 78 | — | — | 2 | 5 | 3 |
%CfB in serum P1NP was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants with postmenopausal osteoporosis.
| Percentage change from baseline | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 4 | 22.10 ± 14.905 | 20.22 ± 15.091 | 19.85 ± 13.939 | 18.45 ± 15.835 | 17.31 ± 15.524 |
| Week 26 | 65.92 ± 17.828 | 62.89 ± 29.294 | 68.42 ± 11.693 | 63.41 ± 42.677 | 66.08 ± 16.098 |
| Week 52 | 65.04 ± 19.131 | 63.82 ± 21.712 | 64.86 ± 16.902 | 66.05 ± 20.428 | 65.89 ± 17.651 |
| Week 78 | — | — | 64.12 ± 18.845 | 66.91 ± 16.816 | 63.08 ± 21.364 |
%CfB in sCTX was assessed as part of pharmacodynamics parameter with US-licensed Prolia® was assessed in female participants with postmenopausal osteoporosis.
| Percentage change from baseline | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 4 | 85.87 ± 9.567 | 85.38 ± 15.501 | 84.96 ± 11.206 | 84.71 ± 23.071 | 88.08 ± 5.832 |
| Week 26 | 69.74 ± 23.212 | 61.51 ± 83.764 | 67.29 ± 23.572 | 53.23 ± 147.679 | 71.27 ± 17.483 |
| Week 52 | 62.90 ± 28.995 | 58.26 ± 63.927 | 60.41 ± 31.958 | 53.89 ± 94.853 | 66.79 ± 24.151 |
| Week 78 | — | — | 58.70 ± 34.117 | 53.32 ± 42.855 | 57.38 ± 30.562 |
The safety and tolerability of RGB-14-P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.
| Participants | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Any AE | 161 | 158 | 0 | 0 | 0 |
| Any TEAEs | 158 | 152 | 30 | 25 | 25 |
| Any TEAEs severe or worse severity | 8 | 9 | 0 | 1 | 0 |
| Any treatment related TEAE | 36 | 32 | 2 | 5 | 1 |
| Any treatment related TEAE severe or worse severity | 1 | 0 | 0 | 0 | 0 |
| Any serious TEAEs | 7 | 16 | 0 | 0 | 0 |
| Any serious TEAEs severe or worse severity | 5 | 9 | 0 | 0 | 0 |
| Any non-serious TEAEs | 158 | 149 | 30 | 25 | 25 |
| Any AEs leading to participant discontinuation | 2 | 3 | 0 | 0 | 0 |
| Any TEAEs leading to subject discontinuation | 2 | 3 | 0 | 0 | 0 |
| Any treatment related TEAE leading to participant discontinuation | 1 | 0 | 0 | 0 | 0 |
| Any TEAEs leading to discontinuation of IMP | 2 | 2 | 0 | 0 | 0 |
| Any treatment related TEAE leading to discontinuation of IMP | 1 | 0 | 0 | 0 | 0 |
| Any fracture TEAE | 9 | 18 | 4 | 3 | 1 |
| Any fracture TEAE severe or worse severity | 2 | 1 | 0 | 0 | 0 |
| Any serious fracture TEAEs | 1 | 1 | 0 | 0 | 0 |
| Any serious fracture TEAEs severe or worse severity | 1 | 1 | 0 | 0 | 0 |
| Deaths | 0 | 1 | 0 | 0 | 0 |
| Any AE leading to death | 0 | 1 | 0 | 0 | 0 |
| Any TEAE leading to death | 0 | 1 | 0 | 0 | 0 |
| Any injection site reactions | 0 | 2 | 0 | 3 | 1 |
| Any treatment related serious TEAE | 0 | 0 | 0 | 0 | 0 |
| Any treatment related serious TEAE severe or worse severity | 0 | 0 | 0 | 0 | 0 |
| Any treatment related fracture TEAE | 0 | 0 | 0 | 0 | 0 |
| Any treatment related fracture TEAE severe or worse severity | 0 | 0 | 0 | 0 | 0 |
| Any treatment related serious fracture TEAE | 0 | 0 | 0 | 0 | 0 |
| Any treatment related serious fracture TEAE severe or worse severity | 0 | 0 | 0 | 0 | 0 |
| Any treatment related fatal serious TEAEs | 0 | 0 | 0 | 0 | 0 |
| Any injection site reactions of CTCAE grade ≥ 3 | 0 | 0 | 0 | 0 | 0 |
| Any injection site reactions severe or worse severity | 0 | 0 | 0 | 0 | 0 |
Number of participants with positive ADAs was assessed.
| Participants | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 0 | 0 | 1 | 0 | 0 | 0 |
| Week 2 | 2 | 0 | 0 | 0 | 0 |
| Week 4 | 0 | 0 | 0 | 0 | 0 |
| Week 26 | 0 | 0 | 0 | 0 | 0 |
| Week 28 | 0 | 1 | 0 | 0 | 1 |
| Week 30 | 0 | 1 | 0 | 0 | 1 |
| Week 52 | 0 | 0 | 0 | 0 | 0 |
| Week 54 | — | — | 0 | 0 | 1 |
| Week 56 | — | — | 0 | 0 | 1 |
| Week 78 | — | — | 0 | 0 | 0 |
Number of participants with positive neutralizing antibodies was assessed.
| Participants | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 0 | — | 0 | — | — | — |
| Week 2 | 1 | — | — | — | — |
| Week 28 | — | 1 | — | — | 1 |
| Week 30 | — | 0 | — | — | 0 |
| Week 54 | — | — | — | — | 1 |
| Week 56 | — | — | — | — | 1 |
The immunogenicity of RGB -14- P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.
| Titre | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Week 0 | NA (NA to NA) | 302.0 (302 to 302) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Week 2 | 761.0 (60 to 1462) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Week 4 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Week 26 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Week 28 | NA (NA to NA) | 172.0 (172 to 172) | NA (NA to NA) | NA (NA to NA) | 172.0 (172 to 172) |
| Week 30 | NA (NA to NA) | 211.0 (211 to 211) | NA (NA to NA) | NA (NA to NA) | 211.0 (211 to 211) |
| Week 52 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Week 54 | — | — | NA (NA to NA) | NA (NA to NA) | 224.0 (224 to 224) |
| Week 56 | — | — | NA (NA to NA) | NA (NA to NA) | 152.0 (152 to 152) |
| Week 78 | — | — | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over Main Period: From screening (Weeks -5 to 0) to Week 52; Transition Period: From Week 52 to Week 78. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Period: RGB-14-P | 0/242 (0%) | 7/242 (2.9%) | 100/242 (41.3%) |
| Main Period: Prolia® | 1/231 (0.4%) | 16/231 (6.9%) | 85/231 (36.8%) |
| Transition Period: RGB-14-P to RGB-14-P | 0/63 (0%) | 0/63 (0%) | 4/63 (6.3%) |
| Transition Period: Prolia® to RGB-14-P | 0/62 (0%) | 0/62 (0%) | 3/62 (4.8%) |
| Transition Period: Prolia® to Prolia® | 0/63 (0%) | 0/63 (0%) | 6/63 (9.5%) |
| Event | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| Meniscus injuryInjury, poisoning and procedural complications | 1/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Radius fractureInjury, poisoning and procedural complications | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Follicular lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/242 | 1/231 | 0/63 | 0/62 | 0/63 |
| Event | Main Period: RGB-14-P | Main Period: Prolia® | Transition Period: RGB-14-P to RGB-14-P | Transition Period: Prolia® to RGB-14-P | Transition Period: Prolia® to Prolia® |
|---|---|---|---|---|---|
| COVID-19Infections and infestations | 25/242 | 24/231 | 0/63 | 0/62 | 0/63 |
| HypocalcaemiaMetabolism and nutrition disorders | 22/242 | 22/231 | 3/63 | 1/62 | 2/63 |
| NasopharyngitisInfections and infestations | 23/242 | 21/231 | 1/63 | 2/62 | 4/63 |
| Upper respiratory tract infectionInfections and infestations | 23/242 | 11/231 | 0/63 | 0/62 | 0/63 |
| HeadacheNervous system disorders | 14/242 | 4/231 | 0/63 | 0/62 | 0/63 |
| HypertensionVascular disorders | 8/242 | 13/231 | 0/63 | 0/62 | 0/63 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/242 | 10/231 | 0/63 | 0/62 | 0/63 |
| Urinary tract infectionInfections and infestations | 11/242 | 11/231 | 0/63 | 0/62 | 0/63 |
The full analysis set (FAS) comprised all participants to whom the investigational medicinal product (IMP) has been randomized. Main period.
| Age, Continuous(Years) | Main Period: RGB-14-P | Main Period: Prolia® | Total |
|---|---|---|---|
| Mean | 66.7 ± 5.20 | 66.8 ± 4.91 | 66.7 ± 5.06 |
| Sex: Female, Male(Participants) | Main Period: RGB-14-P | Main Period: Prolia® | Total |
|---|---|---|---|
| Female | 242 | 231 | 473 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Main Period: RGB-14-P | Main Period: Prolia® | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 22 | 40 |
| Not Hispanic or Latino | 223 | 209 | 432 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Main Period: RGB-14-P | Main Period: Prolia® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 0 | 2 | 2 |
| White | 241 | 229 | 470 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Oct 2023, 24 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 24 months is close to that.
Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osteoporosis, Postmenopausal →
Gedeon Richter Plc.